Zoetis Inc - Class A

ZTS

$176.68

+17.8% last 12 months

Polen Capital Holding value: $954 Million Sands Capital Holding value: $83.3 Million AKO Capital Holding value: $77.1 Million Terry Smith Holding value: $39.3 Million Ray Dalio Holding value: $17.5 Million Mario Gabelli Holding value: $9.68 Million Ron Baron Holding value: $5.6 Million Joel Greenblatt Holding value: $2.11 Million Jefferies Group Holding value: $1.94 Million Ken Fisher Holding value: $297 Thousand Ken Griffin Holding value: $207 Thousand Steven Cohen Holding value: $54.9 Thousand Chuck Royce Holding value: $0 First Eagle Investments Holding value: $0 Gabe Plotkin Holding value: $0 Jim Simons Holding value: $0 Tiger Global Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 Bill Ackman Holding value: $0

Market Cap

$81.3 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$123.32 - $194.99

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

36.74x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$1.45 (0.82%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $81.3 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $86.1 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $1.45 (0.82%)
1 Year Return Profit or loss of share price change plus dividend yield. +18.6%
52-Week High Highest share price in the last 52 weeks. $194.99
52-Week Low Lowest share price in the last 52 weeks. $123.32
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 1.07
Outstanding Shares The number of shares the company has issued and are held by stockholders. 460 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 1.61 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 36.74
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 136.87
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $4.75
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 10.39
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 17.67
Enterprise Value to Revenue Enterprise value divided by revenue 10.48
Enterprise Value to EBIT Enterprise Value divided by EBIT 28.91
Total Debt to Enterprise Value Total debt divided by enterprise value 0.08
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 1.42

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $8.22 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $5.77 Billion
EBIT Earnings before tax and interest payments. $2.98 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $2.21 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 26.92%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +26.8%
Return on Equity Equity divided by market cap. 47.85%
Return on Assets Indicates a company's profitability in relation to its total assets. 16.10%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 24.87%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q4 2022 Q1 2023 Q2 2023 Q3 2023

About Zoetis Inc - Class A

CEO: Kristin Peck

Employees: 9,200

Industry: Pharmaceutical Preparation Manufacturing

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.

Similar stocks

Lilly(Eli) & Co
Lilly(Eli) & Co
Merck & Co Inc
Merck & Co Inc
Pfizer Inc.
Pfizer Inc.
Phibro Animal Health Corp. - Class A
Phibro Animal Health Corp. - Class A
Kindred Biosciences Inc
Kindred Biosciences Inc
Heska Corp. (Restricted Voting)
Heska Corp. (Restricted Voting)
Sanofi - ADR
Sanofi - ADR
Immucell Corp.
Immucell Corp.

News

HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead

HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead

HSBC initiated coverage of 11 US biopharma stocks this week, adding IQVIA, Zoetis, bluebird and Actinium Pharmaceuticals to its buy ratings list. Read more h...

Seeking Alpha Seeking Alpha, 15 days ago
First Commonwealth Financial Corp PA Sells 262 Shares of Zoetis Inc. (NYSE:ZTS)

First Commonwealth Financial Corp PA Sells 262 Shares of Zoetis Inc. (NYSE:ZTS)

First Commonwealth Financial Corp PA decreased its position … during the quarter. First Commonwealth Financial Corp PA’s holdings in …

EIN News Finance EIN News Finance, 16 days ago
Zoetis to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference | ZTS Stock News

Zoetis to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference | ZTS Stock News

Zoetis Inc. will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023. Wetteny

Stock Titan Stock Titan, 19 days ago
Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Zoetis reports strong revenue growth in Q2 2023, with promising market potential. Click here to find out why I advocate for a buy rating for ZTS stock.

Seeking Alpha Seeking Alpha, about 1 month ago
Never miss a trade
To improve your user experience we use cookies.